Through spat with PBMs and insurers, pharma deflects drug-price scrutiny

Under mounting pressure about sky-high drug prices, the pharmaceutical industry has labored over the past year to deflect blame onto pharmacy benefit managers and health insurers. And given the finger-pointing that has resulted, some believe the effort may be working.

Read the full post at
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive